UBE2M Identified by CRISPR Screening as a Key Regulator of Cisplatin-Induced Acute Kidney Injury <i>via</i> the p53 Pathway
UBE2M could serve as a novel therapeutic target for the prevention and treatment of cisplatin-induced nephrotoxicity.
Authors
- Xijie Gao (ORCID: https://orcid.org/0000-0001-8872-2259)
- Danqin Lu
- Lihua Ni
- C. Y. Yuan (ORCID: https://orcid.org/0009-0006-9310-7545)
- Y. Wu (ORCID: https://orcid.org/0000-0003-3192-0486)
- Ayinigaer Yusufu
- Feng Chen
Institutions
- China Three Gorges University (CN)
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Jingzhou Central Hospital (CN)
- Yichang Central People's Hospital (CN)
Publication Details
- Journal
- Endocrine Metabolic & Immune Disorders - Drug Targets
- Published
- 2026-03-12
- DOI
- https://doi.org/10.2174/0118715303410982251112055248
- Primary Topic
- Chemotherapy-induced organ toxicity mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00